
Interim Results (June 2016)

Asian EUS Group (AEG)
Study on EUS Diagnosis of Chronic Pancreatitis
(Phase II)

AEG Multicentre Study in Use of EUS in Investigation of Chronic Pancreatitis




Set of Diagnostic EUS Features to Validate in Asian Population

- 1. Hyper-echoic foci with shadowing
- 2. Lobularity with honeycombing
- 3. Cysts
- 4. Dilated ducts
- 5. Dilated side branches
- 6. Calculi in main pancreatic duct


Conventional Diagnosis of Chronic Pancreatitis Accepted for inclusion as case

- 1. Definitive imaging findings characteristic of chronic pancreatitis on CT/MRCP or ERCP.
- 2. Definitive histological findings characteristic of chronic pancreatitis.


Subject Enrolment by Centre(June 2016)




INDICATIONS FOR EUS CASES/CONTROLS



Diagnosis of Chronic Pancreatitis



Risk Factor Prevalence in Chronic Pancreatitis




Sensitivity, Specificity, Accuracy, NPV and PPV of Individual EUS Feature

	Sensitivity	Specificity	Accuracy	NPV	PPV
Hyperechoic Foci	86.67	97.62	93.79	93.18	95.12
Honeycombing	53.33	92.86	79.07	78.79	80
Cysts	22.22	100	72.87	70.58	100
Dilated Ducts	77.78	97.67	86.82	88.51	83.33
Dilated Side Branches	36.36	98.81	77.34	74.77	94.11
MainPD Calculi	62.22	100	86.82	83.17	100

Hyper echoic foci with shadowing is the most sensitive, and accurate diagnostic EUS Feature in this population.

Sensitivity is low for cysts and dilated side branches but specificity is extremely good

PPV and NPV for EUS Features of CP




PPV and NPV levels are high for all of the 6 diagnostic EUS features

Interim Results (June 2016)

Sensitivity, Specificity by Minimum Number of Diagnostic EUS Features Set as Requirement for Diagnosis of Chronic Pancreatitis

	Sensitivity	Specificity	Accuracy	NPV	PPV
At least 1	95.5	82.1	86.8	97.2	74.1
At least 2	95.5	98.8	97.7	97.7	97.7
At least 3	80	100	93	90.3	100
At least 4	51.1	100	82.9	79.2	100
At least 5	13.6	100	67.8	68.3	100
At least 6	2.3	100	65.9	65.6	100

ROC Curve for No of EUS Features



Optimum number of features = 2 or more (sensitivity 95.5%, specificity 98.8%)

AEG EUS CP CRITERIA (interim)

Chronic Pancreatitis is defined if 2 or more of the following are present on EUS:

- 1. Hyper-echoic foci with shadowing
- 2. Lobularity with honeycombing
- 3. Cysts
- 4. Dilated ducts
- 5. Dilated side branches
- 6. Calculi in main pancreatic duct

Conclusion (interim analyses)

- Continued contribution to the study welcome and more representation from HK/China required
- Study selects 6 EUS features: hyper-echoic foci with shadowing, lobularity with honeycombing, cysts, dilated ducts, dilated side branches and calculi in main pancreatic duct with high interoperator agreement
- These features have been validated to be useful in the defining chronic pancreatitis in this case-cohort.
- Finding 2 of 6 EUS diagnostic features is establishes an EUS diagnosis of chronic pancreatitis in this population.
- Extend study x 3 months till Sep 16 target manuscript Nov 16

Case Record Form

Dear Researcher1 Poon

Thank you for taking time to participate in the Phase II of the study on EUS Diagnosis of Chronic Pancreatitis.


The data you have entered, as shown below, were captured by the system. You may print or save a copy of the data.

Your serial no: 18

Video uploaded: http://www.asianeus.org/wp-content/uploads/gravity_forms/1-64b48acca1d213674c0a1e18628fc40f/2015/12/play-list-14-normal.mp4

Videos will be audited by steering committee

AEG Multicentre Study in Use of EUS in Investigation of Chronic Pancreatitis



The Next Phase...

AEG Surveillance of Chronic Pancreatitis (AESOP)

Study Type: Observational Cohort

Condition: Chronic Pancreatitis as defined by imaging

(CT/MRI/ERCP/EUS)

Surveillance: 1 yearly EUS (and/or adjunctive imaging)

over a 5-10 year period

Primary Outcome Measures: incidence of pancreatic cancer

Secondary Outcome Measure: survival / cause of death

Sample size Estimated: 1000 (50 centres x 20 cases each)

Biospecimen Retention: approximately 40 mls of blood in select centres with support

Assumptions: Incidence rate of 1%, Baseline rate of 0.001%, power 0.8 and α 0.05 n=792

References: Malka Gut 2002;51:849-852; cancer.org accessed 29Jun16

http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-038828.pdf

Thank You